Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of ABI-1179 in Healthy Subjects and HSV-2 Seropositive Subjects
NCT06698575Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of ABI-1179 in genital herpes (5 arms), sponsored by Assembly Biosciences, Inc. Primary endpoints: Area Under the Plasma Concentration Time Curve up to 8 hours, Maximum Observed Plasma Concentration up to 8 hours and 6 more. Started Dec 2024; status: completed.
02
Drugs
ABI-1179
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT06698575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698575.